Large multi-cohort longitudinal evidence base
The analysis covers 60,542 individuals across GNPC, UKB and NSHD, with prospective disease and mortality follow-up in UKB and repeated measurements in NSHD.
↳ Main, study overview; Results; Figs. 1, 3–5
Aging is asynchronous across cells and organs. Here we tested whether plasma proteomics can be used to analyze cell type-specific aging. From analyses of over 7,000 plasma proteins measured in 60,542 individuals, we developed machine learning models to estimate the biological age of over 40 cell types spanning neuronal, immune, glial, endocrine, epithelial and musculoskeletal origins. We observed that 20-25% of individuals exhibited accelerated aging in a single cell type and 1-3% in 10 or more cell types. Cellular aging signatures were associated with disease status and predicted incident disease and mortality over 15 years of follow-up. Individuals with the APOE4 genotype showed older astrocytes but younger macrophages compared to APOE3 carriers, whereas the APOE2 genotype had inverse associations. Moreover, extreme astrocyte aging tripled the risk of incident Alzheimer's Disease in individuals with two APOE4 alleles, while youthful astrocytes reduced risk. Individuals with extremely aged compared to youthful skeletal myocytes exhibited a 12.7-fold higher risk of developing amyotrophic lateral sclerosis. In individuals who smoked, extreme respiratory epithelial cell aging was associated with a 58% higher lung cancer risk compared to smoking alone. Specific cellular vulnerabilities and cumulative cellular aging burden influenced survival, with youthful immune and neuronal cell types conferring protective effects. Finally, we developed a polycellular aging risk score that stratified mortality risk across cohorts and proteomics platforms. These findings establish a framework for quantifying human physiology at cellular resolution, revealing heterogeneous aging trajectories and their impact on disease susceptibility and resilience.
Cellular aging signatures were associated with disease status and predicted incident disease and mortality over 15 years of follow-up.
hazard associations support stratification, but predictive discrimination, calibration and incremental value were not reported
Individuals with extremely aged compared to youthful skeletal myocytes exhibited a 12.7-fold higher risk of developing amyotrophic lateral sclerosis.
the reported association uses a small youthful reference group with uncertain event counts and estimate stability
Extreme astrocyte aging tripled the risk of incident Alzheimer's Disease in individuals with two APOE4 alleles, while youthful astrocytes reduced risk.
cumulative incidence supports the threefold contrast, though the youthful APOE4/4 group contained only 23 participants
In individuals who smoked, extreme respiratory epithelial cell aging was associated with a 58% higher lung cancer risk compared to smoking alone.
the reported hazards support the contrast, with observational adjustment rather than clinical prediction testing
We developed a polycellular aging risk score that stratified mortality risk across cohorts and proteomics platforms.
one external cohort and cohort-specific percentile thresholds support stratification but not platform-agnostic deployment
Derived from the full evaluation — not a separate score.
Strengths
The analysis covers 60,542 individuals across GNPC, UKB and NSHD, with prospective disease and mortality follow-up in UKB and repeated measurements in NSHD.
↳ Main, study overview; Results; Figs. 1, 3–5
Olink clocks and PARS were developed in the UKB training partition and evaluated in a held-out test partition, while PARS was also applied to SomaScan measurements in NSHD.
↳ Methods, Cellular Age Estimation and PARS Development; Fig. 5e–f
The study benchmarks astrocyte aging against APOE4, PRS and age, adjusts respiratory signatures for smoking exposure, and repeats the ALS analysis after a three-year diagnostic lag.
↳ Fig. 3f; Extended Data Figs. 6 and 9; Methods, Prognostic Analysis
Limitations
The disease and mortality analyses emphasize hazard ratios and survival separation without reporting discrimination, calibration or broad comparisons against established clinical and general proteomic prognostic models.
↳ Results, Figs. 3–5; Methods, Prognostic Analysis and PARS Development
The analysis does not compare the assigned panels with matched random protein sets, whole-proteome models or organ clocks, so the endpoint value attributable to cell-type mapping is unresolved.
↳ Methods, Identification of Cell Type-Enriched Plasma Proteins and Cellular Age Estimation
The Discussion acknowledges that plasma proteins may be produced or released more broadly, yet the conclusions retain cellular-resolution and therapeutic interpretations.
↳ Discussion, limitations and conclusion
The study's strongest features are its scale, center-based UKB train-test design, prospective follow-up and application of PARS across Olink and SomaScan. Its methodological score is constrained because hazard ratios and Kaplan–Meier curves do not establish prediction quality without discrimination, calibration and fair prognostic comparators. The absence of matched non-cell-specific or organ-clock analyses also leaves the added value of cell-type assignment unresolved. The paper acknowledges plasma-source ambiguity, but its cellular-resolution and therapeutic framing remains broader than that limitation supports.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study meaningfully extends plasma aging-clock work to putative cell-type signatures across 60,542 participants, three cohorts and two assay platforms. The advance is tempered by the absence of direct endpoint comparisons with organ-level or general proteomic clocks.
We map plasma proteins to their putative cellular origin and construct computational models that measure the biological age of over 40 cell types.
The UKB center-based train-test split, bootstrap aggregation, disease-specific adjustments and NSHD evaluation support the analysis. The central prediction framing lacks discrimination, calibration and broad prognostic baselines, while no matched ablation establishes that cell-type assignment adds endpoint-relevant information.
Participants were stratified into high, medium, and low risk groups based on cohort-specific score distributions.
The manuscript follows a coherent progression from protein mapping and clock construction to disease, mortality and PARS analyses. However, statements that the signatures predict or strongly prognosticate disease imply validated predictive performance beyond the reported hazard and survival separation analyses.
Our findings reveal cellular aging signatures strongly prognosticate future disease.
The paper positions the work against organ-level and tissue-based aging clocks and acknowledges transcript-to-protein and population limitations. Its conclusions nevertheless retain cellular-resolution and therapeutic interpretations that the plasma-source ambiguity materially narrows.
Plasma proteins arise from multiple cellular processes not explicitly disentangled here.
Caveats3 of 4 checks
One reported value does not reconcile, but the key claims do not rest on it.
The NSHD longitudinal mortality methods describe deaths as censoring, whereas the figure caption describes death as the event; the supplied text does not establish how the analysis actually encoded deaths.
Ethics approval: declared · Data availability: declared
Reference integrity check could not run: references could not be reliably parsed from the manuscript; verification skipped rather than risk false verdicts.
0 references in manuscript
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The prognostic claim was tested prospectively in three independent cohorts across two proteomics platforms, with external validation in the NSHD cohort and 15-year follow-up, but not in routine clinical use.
“underscoring potential for targeted surveillance and early preventive interventions”
The paper names real-world uses of its findings, such as presymptomatic detection, risk stratification and targeted surveillance, but does not specify which professionals or organisations would apply them.
Clinicians could use these plasma-based cellular aging scores as blood biomarkers to stratify patients for presymptomatic disease screening and targeted preventive surveillance.
The associations need prospective demonstration that risk stratification changes clinical management or outcomes, plus validation in younger and more diverse populations before clinical adoption.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Robinson, Xiao, Homann, et al. · 2026 · Clinical medicine
the global age gap, an age acceleration score combining proteomic clocks, was associated with smoking, alcohol consumption, physical inactivity and higher risk of mortality, cardiovascular diseases, dementia and cancers of the liver, upper aero-digestive tract, lung and kidney.
SupportedFreya Lyssy, Jacqueline Guettler, Beatrice A Brugger, et al. · 2023 · Basic medicine
S1PR2 was found to be significantly down-regulated in BeWo cells when co-incubated with platelet-derived factors (P = 0.0055).
TentativeNadja Kupper, Berthold Huppertz · 2021 · Basic medicine
in pregnancy pathologies such as preeclampsia, quantity and quality of the placenta-derived vesicles are altered leading to a deleterious effect on the maternal vascular system.
Tentative